SubscribeThe agreement between SickKids and Afference includes the licensed patents, technology, and intellectual property related to neuropeptides and sensory (pain) nerves, as well as future patents generated by the research program.If they've already spun off the research arm and are "going corporate" they must be pretty confident that they're headed in the right direction. Someone evidently tried to get more information from the doctors on the program and received this response from Dr. Dosch at SickKids, which sounds extremely hopeful:
"I am able to state that our confidence to be able to translate our findings to human diabetes has distinctly grown..."Science slowly marches on...
"...Our main clinical plan in both Type 1 and Type 2 diabetes patients is:We expect to begin intervention studies in 2008."
- Expand specific studies of patient responses to neuromodulators
- Complete regulatory approval process towards phase-1 trials in Type 1 and Type 2 diabetes patients
- Conduct neurological, non-invasive studies of afferent (pain) nerve sensitivities
- Collect patient blood samples for genetic sequencing studies of identified molecules suspected to play a role in human diabetes.
« Older 201 Stories by Anton Chekhov... | Exposition Universelle et Inte... Newer »
This thread has been archived and is closed to new comments
posted by wendell at 1:19 AM on November 11, 2007